WITHDRAWN: Chemerin and Sfrp5 levels in Subclinical Hypothyroid

Abstract Purpose Thyroid dysfunction causes changes in adipokine and lipid profiles. Chemerin and Sfrp5 are adipokines with known effects on inflammation, but their relationship with thyroid hormones is not well clearly understood. This study aimed to investigate the effect of subclinical hypothyroidism on chemerine and Sfrp5 levels. Methods Serum chemerin, Sfrp5, LDL kolesterol, total kolesterol, trigliserid, HDL kolesterol, insulin, glucose, HOMA-IR, systolic-diastolic blood pressure, waist circumference, and BMI were measured in 46 subclinical hypothyroidism patients and in 49 healthy control subjects. Results While the patient group had higher serum chemerin levels and lower Sfrp5 levels compared to the control group, no statistically significant difference was found. When other parameters in the serum were examined, there was no significant difference between the groups. When both the patient and control groups were considered together, a significant positive correlation was found between chemerin and Sfrp5 levels and negative corelation was observed between Sfrp5 and LDL cholesterol, total cholesterol, triglycerides, BMI, diastolic blood pressure, systolic blood pressure, waist circumference values. Conclusion High levels of chemerin and low levels of Sfrp5 in subclinical hypothyroidism suggest that these two proteins may be associated with the disease. We found no statistically significant differences. This may be due to the fact that the participating patients had mild subclinical hypothyroidism and the inflammation was not at an advanced stage. Additionally, Sfrp5 is associated with metabolic syndrome parameters independent of subclinical hypothyroidism.